entertainment -WSS

entertainment

author：leisure time 2025-10-01 01:57:43 - browse：539

Sarepta - Cambridge -AP — A logo sign outside of the headquarters of Sarepta Therapeutics in Cambridge, Mass. Kristoffer Tripplaar/Sipa via AP

Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to intervene earlier this year, according to three people with direct knowledge of the agency deliberations.

Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta’s gene therapy should be rejected, the individuals said, speaking on condition of anonymity. Peter Marks, a top FDA official and vocal advocate for faster gene therapy approvals, stepped in and directed staff to schedule a public hearing on the therapy on May 12.

Sarepta announced the scheduling of the public hearing last month, but the internal deliberations that led to it have not been previously reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Diversity in clinical trials starts with building trust, experts say

Wikipedia

WSS

Telehealth startups are trying to fill the menopause care vacuum

Dogs on Prozac: What pet anti

Cue Health's Covid

A new ‘biological computer' targets cancer while sparing healthy cells

Why rehabilitation engineers need to center patients in their research

Extensive review finds private equity owners jack up cost of care

explore

entertainment

leisure time

Walensky prepares to leave CDC — and Congress — behind

Telehealth startups are trying to fill the menopause care vacuum

DIEP, the 'gold standard' of breast reconstruction, is under threat

There’s a way to spot data fakery. All journals should be using it

23andMe had bad news about my health. I wish a person had delivered it

Bird flu outbreak in cows is latest avian flu curveball

Psychedelics group wrestles with new pharma identity

Getting Alzheimer's drug Leqembi to patients can be a challenge

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

explore

There’s a way to spot data fakery. All journals should be using it

Stanford president’s abrupt resignation sparks debate

Stanford president’s abrupt resignation sparks debate

After traumatic brain injury, life support decisions can use more time

Why rehabilitation engineers need to center patients in their research

Medical bills so high, Medicare adding extra digits to claim forms

knowledge

Wikipedia

entertainment

explore